Revidia Therapeutics, Inc.
Lamoine, ME
- UEI
- W129EFQ5LL71
- CAGE
- 6XGH9
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 22 Partridge Cove Rd, Lamoine, ME 04605, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy… | National Heart Lung and Blood Institute | $1,358,151 | |
| Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial… | National Heart Lung and Blood Institute | $1,495,751 |
Quick answers
What is Revidia Therapeutics, Inc.'s UEI?
Revidia Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is W129EFQ5LL71.
What is Revidia Therapeutics, Inc.'s CAGE code?
Revidia Therapeutics, Inc.'s CAGE code is 6XGH9.
Where is Revidia Therapeutics, Inc. located?
Revidia Therapeutics, Inc.'s physical address in SAM.gov is 22 Partridge Cove Rd, Lamoine, ME 04605, USA.
Is Revidia Therapeutics, Inc. registered in SAM.gov?
Yes. Revidia Therapeutics, Inc.'s SAM.gov registration is active through May 3, 2027.
What is Revidia Therapeutics, Inc.'s most recent federal award?
Revidia Therapeutics, Inc.'s most recent federal grant award is IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy… (R44HL174171), from National Heart Lung and Blood Institute, on September 20, 2024.
On GovTribe
See Revidia Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors